Filed by Motion Acquisition Corp.
Pursuant to Rule 425 under the Securities Act of 1933
and deemed filed pursuant to Rule 14a-12
under the Securities Exchange Act of 1934
Subject Company: Motion Acquisition Corp.
Related Registration Statement File No. 333-257681



Disclaimer



resentation contemplates a business combination pursuant to a merger agreement, by and among Ambulnz Inc. (dba "DocGo"), Motion Acquisition Corp. ("Motion"), and a wholly owned subsidiary of Motion, dated as of March 9, 2021. This presentation discusses the proposed business combination and does not purport to be all-inclusive or to give you any legal, tax or financial advice. This presentation does not constitute or involve, and should not be taken as constituting or involving, the giving of any investment advice, the making of any representation, warranty or coverant whatsoever, or as a recommendation with respect to the voting, purchase or sale of any security or as to any other matter by DocGo, Motion or any other person.

Although the information contained herein is believed to be accurate, DocGo and Motion, as well as each of their respective directors, officers, shareholders, members, partners and representatives, expressly disclaim liability for, and makes no expressed or implied representation or warranty with respect to, any information contained in or omitted from this presentation, or any other information or communication (whether written or oral) transmitted to any prospective investor. Only those representations and warranties made in a definitive agreement with any person shall have any legal effect.

This presentation does not constitute (i) a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed business combination between DocGo and Motion or (ii) an offer to sell, a solicitation of an offer to buy, or a recommendation to buy any security of Motion, any company forming a part of DocGo or any of their respective affliates. There shall not be any sale of any securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such other jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Investors should make their own independent investigation of DocGo and Motion before investing in any securities.

PAST PERFORMANCE IS NO GUARANTEE OF FUTURE PERFORMANCE.

<u>Use of Projections and Financial Information</u>
This presentation contains financial forecasts relating to the anticipated future financial performance of the proposed combination of DocGo and Motion and are subject to risks and uncertainties that could cause actual results to differ materially from those statements and should be read with caution. They are subjective in many respects and thus susceptible to interpretations and periodic revisions based on actual experience and recent developments. While presented with numerical specificity, the projections were not prepared in the ordinary course and are based upon a variety of estimates and hypothetical assumptions made by management of DocGo and Motion with respect to, among other things, general economic, market, interest rate and financial conditions, the availability and cost of capital for future investment, and competition within DocGo's markets. The projections were not prepared with a valve toward compliance with published guidelines of the SEC, the guidelines established by the American institute of Certified Public Accountants for prospective financial information or generally accepted accounting principles in the United States of America ("GAAP")

None of the assumptions underlying the projections may be realized, and they are inherently subject to significant business, economic and competitive uncertainties and risks, all of which are difficult to predict and many of which are beyond the control of DocGo and Motion. Accordingly, there can be no assurance that the assumptions made in preparing the projections will prove accurate, and actual results may materially differ. Furthermore, while all projections are necessarily speculative, DocGo and Motion believe that prospective financial information covering periods beyond 12 months from its date of preparation carries increasingly higher levels of uncertainty and should be read in that

For these reasons, as well as the bases and assumptions on which the projections were compiled, the inclusion of the information set forth below should not be regarded as an indication that the projections will be an accurate prediction of future events, and they should not be relied on as such. Neither DocGo nor Motion or any of their respective affiliates, advisors or other representatives has made, or makes, any representation to any stockholder or prospective investor regarding the information contained in the projections and, except as required by applicable securities laws, neither DocGo nor Motion intends to update or otherwise revise the projections to reflect the occurrences of future events even in the event that any or all of the assumptions are shown to be in error.

Non-GAAP Financial Information

This presentation also includes references to financial measures that are calculated and presented on the basis of methodologies other than in accordance with GAAP, such as Earnings Before Interest, Tax, Depreciation and Amortization ("BBTDA") and Adjusted BBTDA. As a result, such information may not conform to SEC Regulation SEC Regulation ("BBTDA") and Adjusted BBTDA. As a result, such information may not conform to SEC Regulation SEC Regulation SEC Regulation and used in this presentation are in addition to, and should not be considered superior to, or a substitute for, financial statements prepared in accordance with GAAP. Non-GAAP financial measures are subject to significant inherent limitations. The non-GAAP measures presented define may not be comparable to similar non-GAAP measures presented by other companies. This information may be presented differently in future filings by the company with the SEC.

Disclaimer (cont'd)



Market and Industry Data

Market data and industry data used throughout this presentation is based on information derived from third party sources, the knowledge of the management teams of DocGo and Motion regarding their respective industries and busines and respective management teams' good faith estimates. While management of DocGo and Motion believe that the third party sources from which market and industry data has been derived are reputable, DocGo and Motion have not independently verified such market and industry data, and you are cautioned not to give undue weight to such market and industry data.

This presentation relates to a proposed business combination between DocGo and Motion, as further described in that certain definitive proxy statement/consent solicitation/prospectus filed with the SEC on October 14, 2021, and certain related documents, to be used at the meeting of Motion stockholders to approve the proposed business combination and related matters. Investors and security holders of Motion are urged to read the definitive proxy statement/consent solicitation/prospectus, accompanying registration statement, and any amendments thereto, and all other relevant documents filed or that will be filed with the SEC in connection with the proposed business combination as they become available because they will contain important information about DocGo, Motion, and the proposed business combination. The definitive proxy statement/consent solicitation/prospectus will be mailed to Motion stockholders of record as of September 9, 2021. Investors and security holders are able to obtain free copies of the registration statement, the definitive proxy statement/consent solicitation/prospectus will be mailed to Motion stockholders of record as of September 9, 2021. Investors and security holders are able to obtain free copies of the registration statement, the definitive proxy statement/consent solicitation/prospectus will be mailed to the finitive proxy statement/consent solicitation/prospectus will be mailed to the registration statement, the definitive proxy statement/consent solicitation/prospectus will be mailed to the finitive proxy statement/consent solicitation/prospectus will be mailed to the finitive proxy statement/consent solicitation/prospectus will be mailed to the finitive proxy statement/consent solicitation/prospectus will be mailed to the finitive proxy statement/consent solicitation/prospectus will be mailed to the finitive proxy statement/consent solicitation/prospectus will be mailed to the finitive proxy statement/consent solicitation/prospectus will be mailed to the finitive proxy statement/consent solicitation/prospectus will be mailed to the proposed business combination at the proposed business combin charge at Motion's website at https://motionacquisition.com or upon written request to Motion's counsel, Graubard Miller, 405 Lexington Avenue, New York, NY 10174.

Solicitation Participants

DocGo and Motion and their respective officers and directors, under SEC rules, may be deemed to be participants in the eventual solicitation of proxies of Motion's stockholders in connection with the proposed business combination. Prospective investors may obtain more detailed information regarding the names and interests in the proposed business combination of such individuals in Motion's filings with the SEC. A list of the names of such directors and executive officers and information regarding their interests in the proposed business combination will be contained in the definitive proxy statement/prospectus. You may obtain free copies of these documents as described in the preceding paragraph.

Certain statements included in this presentation are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook," and similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding estimates and forecasts of other financial and performance metrics and projections of market opportunity

These statements are based on various assumptions, whether or not identified in this presentation, and on the current expectations of DocGo's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of DocGo and Motion. Some important factors that could cause actual results to differ materially from those in any forward-looking statements are subject to a number of risks and uncertainties, including the required approval by DocGo's and Motion's stockholders, may not be satisfied on the terms expected or on the anticipated schedule; the parties' ability to meet expectations the conditions to the completion of the merger, including the required approval by DocGo's and Motion's stockholders, may not be satisfied on the terms expected or on the anticipated schedule; the parties' ability to meet expectations regarding the timing and completion of the merger agreement; the outcome of any event, change or other circumstance that could give rise to the termination of the merger agreement; the approval by Motion's stockholders of an amendment to Motion's organizational documents to extend the date by which Motion must complete its initial business combination in order to have adequate time to close the proposed business combination; the outcome of any legal proceedings that may be instituted against Motion related to the merger agreement; and the amount of the costs, fees, expenses and other charges related to the merger; the risk that any required regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the combined company or the expected benefits of the proposed business combination; failure to realize the anticipated benefits of the proposed business combination; as the uncertainty of the projected financial information with respect to DocGo; DocGo's ability to successfully expand its service offerings; competition; the uncertainty of the projected financial information with respect to DocGo; DocGo's ability to successfully expand its service offerings; competition; the uncertainty of the projected financial information with respect to DocGo; and observate as service offerings; competition; the uncertainty of the projected financial information with respect to DocGo; and Motion as assessments to delay the service offerings; competition; the uncertainty of these risks materialize or our assumptions prove incorrect, actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect DocGo and Motion articipate that subsequent events and developments will exact a some point in the future, DocGo and Motion specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing DocGo's and Motion's assessments as of any date subsequent to the date of this presentation. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Disclaimer (cont'd)



Forward Looking Statements (cont'd)

Any financial projections in this presentation are forward-looking statements that are based on assumptions that are inherently subject to significant uncertainties and contingencies, many of which are beyond DocGo's and Motion's control. While all projections are necessarily speculative, DocGo and Motion believe that the preparation of prospective financial information involves increasingly higher levels of uncertainty the further out the projection extends from the date of preparation. The assumptions and estimates underlying the projected results are inherently uncertain and are subject to a wide variety of significant business, economic and competitive risks and uncertainties that could cause actual results to differ materially form those contained in the projections. The inclusion of projections in this presenttion should not be regarded as an indication that DocGo and Motion, or their respective representatives and advisors, considered or consider the projections to be a reliable prediction of future events.

This presentation is not intended to be all-inclusive or to contain all the information that a person may desire in considering an investment in Motion and is not intended to form the basis of an investment decision in Motion. All subsequent written and oral forward-looking statements concerning DocGo and Motion, the proposed business combination or other matters and attributable to Motion, DocGo, or any person acting on their behalf are expressly qualified in their entirety by the cautionary statements above

Cautionary Statement Regarding Preliminary Estimated Results
The financial results for DocGo's third quarter ended September 30, 2021 (as seen on Slide 25 and referenced throughout the presentation) are preliminary, unaudited and subject to finalization. They reflect DocGo management's current views and may change as a result of DocGo's further review of results and other factors, including a wide variety of significant business, economic and competitive risks and uncertainties. Such preliminary results should not be viewed as a substitute for full quarterly financial statements and accompanying footnotes prepared in accordance with GAAP. Motion and DocGo caution you that these preliminary results are not guarantees of future performance or outcomes, and that actual results may differ materially from those described above, Permore information regarding factors that could cause actual results to differ from those described above, please see "Cautionary Statement". Regarding Forward-Looking Statements" above

The preliminary third quarter financial results have been prepared by, and are the responsibility of, DocGo's management. DocGo's independent registered public accounting firm has not audited, reviewed, compiled, or applied agreed-upon procedures with respect to the preliminary estimated financial information, and does not express an opinion or any other form of assurance with respect thereto.

No representation or warranty, express or implied, can be made or is made by DocGo or Motion as to the accuracy or completeness of any such information. Except where otherwise indicated, this presentation speaks as of the date hereof and is necessarily based upon the information as of the date hereof, all of which are subject to change. DocGo and Motion have no obligation to update, bring-down, review or reaffirm this presentation. Under no circumstances should the delivery of this presentation imply that any information or analyses included in this presentation would be the same if made as of any other date. Nothing contained in this presentation is, or shall be relied circumstances should the delivery of this presentation imply that any informupon as, a promise or representation as to the past, present or future.

This presentation provides summary information only and is being delivered solely for informational purposes. The recipient of this presentation acknow

- · DocGo and Motion do not provide legal, tax or accounting advice of any kind
- It is not relying on DocGo or Motion for legal, tax or accounting advice, and that the recipient should receive separate and qualified legal, tax and accounting advice in connection with any transaction or course of conduct.
- . Nothing contained herein shall be deemed to be a recommendation from DocGo or Motion to any party to enter into any transaction or to take any course of action.
- . This presentation is not intended to provide a basis for evaluating any transaction or other matter
- · Neither DocGo nor Motion shall have any liability, whether direct or indirect, in contract or tort or otherwise, to any person in connection with this presentation

INVESTMENT IN ANY SECURITIES DESCRIBED HEREIN HAS NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND EXCHANGE COMMISSION OR ANY OTHER REGULATORY AUTHORITY, NOR HAS ANY REGULATORY AUTHORITY PASSED UPON OR ENDORSED THE MERITS OF THE OFFERING OR THE ACCURACY OR ADEQUACY OF THE INFORMATION CONTAINED HEREIN. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. THIS PRESENTATION DOES NOT CONSTITUTE AN OFFER OR SOLICITATION OF ANY SECURITIES.



Our Brand and Company Culture

Where basic telehealth providers stop, we go.

Where public health emergencies need a response, we go. Where homebound populations benefit from onsite treatment, we go. Where long waits in busy emergency rooms do more harm than good, we go.

And when all reason says it can't be done, leave well enough alone and quit while you're ahead, we do what our Company has always done.

DocGo. We go.

Our Model



Fulfilling the Promise of Telehealth by Enabling the "Last-Mile" Delivery of Healthcare

DocGo at a Glance



Key Highlights (\$ in millions)

















Leveraging a proprietary technology platform and care logistics expertise to provide high quality, efficient "last-mile" healthcare delivery services

(a) Rating based on 300+ reviews. (b) As of Sept 2021.

Summary Progress Report Since Transaction Announcement in March 2021



Where we were:	Where we are today:
\$155mm 2021E Revenue Guidance	\$260mm 2021E Revenue Guidance (68% increase)
\$6mm 2021E Adjusted EBITDA Guidance	\$10mm Adjusted EBITDA Guidance (67% increase)
Presence in 23 Markets in the US and 1 internationally	Presence in 28 Markets in the US and 1 internationally (new markets: MI,LA,AZ,MD,WA)
1,700+ healthcare clinicians	3,500+ healthcare clinicians
\$72 million in Mobile Health contracts	>\$135 million in Mobile Health contracts

Where Traditional Care Stops, DocGo Keeps Going





Traditional Care vs. Mobile Health


Traditional Care

- Patients are restricted by outdated logistics and expensive transportation solutions
- Limited options to get treated at home or on-site
- Current telehealth offerings do not provide immediate in-person care or follow-up as needed

DocGo Mobile Health Solution

- Mobility solutions that are enabled by highly coordinated and efficient logistics capabilities
- Mobile Health offering goes far beyond traditional telehealth capabilities, delivering true "last-mile" services
- Unique solution set plugs seamlessly into existing care ecosystem

© 2021 All Rights Reserved - DocGo



Illustrative Customers, Partners & Projects




Tailored Go-to-Market for each Customer Segment

Government Enterprise / Corporates Health Systems



© 2021 All Rights Reserved - DocGo



Purpose-Built Technology Platform



Core Functionality and Benefits Streamlined ordering process to reduce burden on staff Integration of electronic health records Easy ordering with no manual information transfer Real-time visibility into transport status and ordering For Facilities For Patients and Families For Care Providers For Facilities For Pacilities For Pacilities For Pacilities Two apps. One location-based dispatch system. Connected.

Fully-Integrated Front- and Back-End Tech



Multi-modal Software to Better Coordinate Care



EASY ORDERING

 Digital requesting via Web, Mobile, Epic, Allscripts, Mobile Care Connect and Central Logic




TOTAL TRANSPARENCY

 Integrated systems providing tracking for hospital staff, receiving facility and family members



DEDICATED SUPPORT LINE

A human being in seconds



Modern Architecture and Design

EHR INTEGRATION

Integrated with leading EHR providers enhances functionality & billing/collections



MACHINE LEARNING / AI

- State-of-the-art system with proprietary Alpowered algorithms
- Proprietary artificial intelligence-based scheduling (CAD) system with Google traffic data

SHARELINK™

 ShareLinkTM technology provides hospitals, patients and their caregivers real-time vehicle location, accurate ETAs and peace of mind

HIPAA COMPLIANT

 Designed for managing sensitive healthcare data

Our digital platform is fully integrated with industry standard EHR providers and enables a seamless care logistics experience throughout the patient journey

Segment Overview – Medical Mobility




AMBULNZ MEDICAL MOBILITY SOLUTIONS

ambulnz



- Provides on-demand patient transfer solutions between clinical settings
- Partnerships with Fresenius, Jefferson, UCHealth and Northwell
- 300+ fleet of vehicles include ambulances, wheelchair vans and sedan to accommodate each unique request
- Proprietary algorithm and clinical system integration optimize patient transfers



Telemedicine is Just Talk – Mobile Health is Hands On



DocGo. We're There.

Leveraging Advanced, Mobile Technologies to Deliver Robust Services Oral Medicine Bloodwork **IV** Hydration **Wound Care** Mobile Imaging EKG Vaccinations Administration M For Patients... At home treatment is convenient, comfortable and results in an improved patient experience Accessibility to health professionals promotes better patient compliance with discharge treatment plans More focused care reduces unnecessary hospital readmissions For Providers... DocGo employed clinicians, consisting of paramedics and EMTs, can provide care at a lower cost than LPNs/LVNs or physicians Reduces overall healthcare costs by preventing unnecessary flow of patients into healthcare facilities al Nurse, LVN = Licensed Vocational Nurs

© 2021 All Rights Reserved - DocGo

Overview of Mobile Health Services



2020 Patient Interactions

2021E Patient Interactions

~68k

~250k

Bedside Procedures

- · Rapid testing (blood work, including routine tests like Coumadin levels, Pregnancy, Strep, Urinalysis, Viruses (COVID-19, HIV))
- · Pre-op testing
- · Pulse oximetry
- Ultrasound
- Wound Care

Medications (Oral and IV)

- · 30+ oral medications available, including antibiotics and anti-nausea medications
- Asthma treatments
- Intravenous fluids

Cardiac

- · Blood pressure monitoring
- Cardiac monitoring
- Echocardiogram
- Electrocardiogram (EKG)

Preventative Care

- · Vaccinations (Influenza, Hepatitis,
- · Medicine reconciliation

Pneumonia, Tetanus)

- · Physicals (school, sports)

~\$125

2021E Revenue per Interaction

~50%

2021E Gross Margin

Mobile Health is hands on. Delivering on the promise and potential of telemedicine.

© 2021 All Rights Reserved - DocGo

Segment Overview – Mobile Health



MOBILE HEALTH SOLUTIONS



















- Provided mobile health services to multiple clients including Uber, HBO, NFL, GoodRx, and the state of New York
- Working together with licensed medical practitioners, we facilitate in-person services and follow-up treatment where a traditional doctor's visit is not necessary
- Services include bedside procedures, preventative care, medicine administration, monitoring and various vaccinations
- Utilizes existing medical employees to deliver services at a lower cost
- 2021E Mobile Health Revenue of \$43mm excludes COVID-19 testing revenues



Case Study: Department of Homeless Services






a) According to National Alliance to End Home

Our Footprint and Reach





Quality Employed Clinicians



2,400+ highly trained clinicians

Employed mobile clinicians consisting of

- EMTs (2,100+)
- Paramedics (230+)
- Nurses & RTs (79+)

Employed, Not Contracted

Revolutionary pay package elevates employees far above the national average with added benefits

- Medical insurance
- Performance bonus
 - Paid time off
- Equity incentive plan to earn ownership in Ambulnz

- Improved patient care
- Improved loyalty to company
- Improved employee NPS
- Improved facility NPS
- Improved insurance rates






© 2021 All Rights Reserved - DocGo

Network Effect Drives Efficiencies of Scale



Highly Replicable Go-to-Market Strategy




(a) May enter certain markets before ambulance operations, based on consumer demand.

Significant Market Opportunity

\$95 billion market opportunity leaving long runway for rapid growth

U.S. Total Addressable Market



Source: McKinsey "Telehealth: A quarter-inition-dollar-post-COVID-19 reality" report published 5/1/20 and management estimate

© 2021 All Rights Reserved - DocGo



- Approx. \$250B or approx. 20% of all Medicare, Medicaid & Commercial outpatient, office and home health spend could be virtual
- However, approx. \$80B of this spend requires some form of physical follow up that lacks a solution today
- The medical transportation industry remains very fragmented and is expected to continue to grow steadily, driven by an increasingly aging population and rising prevalence of chronic diseases
- Rapid acceleration in shift to virtual care driven by COVID-19
- DocGo is active in some of the largest, most attractive markets in the U.S. with massive untapped opportunity remaining in the markets already penetrated

Attractive Financial Characteristics







- Significant revenue growth opportunity with limited penetration of the total market and existing newer markets, greenfield opportunities and expansion of new services offerings
- Recurring revenue with visibility from multi-year, contracted strategic partner relationships with over \$500mm in contracted revenue

Scalability



- Diversified base of customers and strategic partnerships allowing for opportunity to upsell new products and expand geographically with existing strategic partners
- Tested scalable execution model, utilizing refined process and technology allows for rapid growth into new markets and grow existing markets

Profitability and Capital Efficiency




- · Capital efficient business model through leased vehicles
- Use of technology and business optimization enhances profitability, Adjusted EBITDA positive in 2021E
- Expanding Gross Margins with medium-term opportunity toward 50% gross and 20% Adj. EBITDA margins


Strong Growth Trajectory and Margin Profile



\$10

\$44





Adjusted EBITDA

(\$7)

Q3 2021 Financial Update

(\$ in millions)





© 2021 All Rights Reserved - DocGo



Preliminary 3rd Quarter 2021 Financial Highlights and Year to Date September 30, 2021 review

- Mobile Health revenue increased 432% to +\$60 million in Q3 2021, compared to \$11 million in the PY Q
- Medical Mobility revenues increased 32% to +\$20 million in Q3 2021, compared to \$15M in the PY Q
- Excluding COVID-related testing from both periods, Q3 revenue expected to triple year-over-year
- Mobile Health revenue growth driven by several large new and expanded contracts
- · Revenue guidance for the full-year 2021 increased from \$170 million to \$260 million
- · Adjusted EBITDA guidance for the full-year 2021 increased from \$6 million to \$10 million

Third Quarter 2021 Business Highlights

- · Hired 780 new employees in Q3 2021, total headcount at a new record of over 2,900 employees
- · Launched medical transportation services in London, and mobile health services in Maryland and Michigan
- · Partnered with NYC Health + Hospitals, launching largest US public flu testing program
- · Drove incremental revenue from the NYC Street Health Outreach and Wellness (SHOW) program (providing Mobile Health services, such as wound care, physicals, social work services and a variety of vaccines NYC's homeless population)

Key Takeaways



Significant market and growth opportunity with limited current market penetration

Early stages of accelerating recurring revenue growth

Unique value proposition to healthcare systems and patients

Defensible competitive advantages in technology / network

Highly attractive financial profile with significant operating leverage

Mission-driven company with experienced founder-led management




Pro Forma Capitalization & Ownership



Estimated Transaction Sources & Uses		
(\$ in millions)		
Sources		
SPAC Cash in Trust	\$115	
PIPE Investor Cash	\$125	
Total Sources	\$240	
Uses		
Cash to Balance Sheet	\$205	
Transaction Expenses	\$35	
Total Uses	\$240	

\$ in millions)		
Pro forma Transaction		
DocGo Illustrative Share Price	\$10.00	
Pro forma Shares Outstanding ^{(a)(b)}	110.5	
otal Equity Value	\$1,105	
+) Proforma Net Debt at Close	(205)	
Pro forma Enterprise Value	\$900	


Illustrative Post-Transaction Ownership



(a) Assumes no rederations of public shares and excluding warrants.
(b) Does not instacte an aggregate 5.0M seltler enrous shares subject to vesting upon affairment of stock price targets ranging from \$12.50 to \$21.00 over periods ranging from one to five years. Excludes Motion warrants.

Comparable Company Benchmarking





(a) Pro forms for first friesth acquisition.
(b) 2019 figures represents standalone ACCD and exclude impact of 2ND.MD and Plushcare acquisitions; excludes earnout consideration associated with the 2ND.MD acquisition.
(c) Excludes per forms financiate for 2ND.MD and Plushcare acquisitions.
(d) Pro forms for Liverage Health acquisition.
Source: Company information, FactSet. Market data as of ff-October-21.

② 2021 All Rights Reserved — DocGo 29

Comparable Company Benchmarking (cont'd)





Note: Existudes multiplies >100.00.

(a) EV impressible originates value at announcement; assumes no redemp
(b) Pro forms for lora Health acquisition.

(c) Excludes pro forms forancials for 2MD.MO and Plushcere acquisitions.

Source: Company information, FlactSet Methed date as of 11-October-21.

□ 2021 All Rights Reserved — DocGo. ement; assumes no redemptions and share price of \$10.